DPP4 and myocardial infarction: In addition, the evidence from some clinical studies supporting a positive effect in the setting of myocardial infarction and percutaneous coronary revascularization represents an important challenge for the expansion of GLP-1 RA e DPP4-i therapeutics in non-diabetic patients other than diabetics.